Vasopressin has many physiological actions in addition to its well-defined role in the control of fluid homeostasis and urine concentration. An increasing body of evidence suggests that the vasopressin-hydration axis plays a role in glucose homeostasis. This review summarizes the knowledge accumulated over the last decades about the influence of vasopressin in the short-term regulation of glycaemia. It describes the possible role of this hormone through activation of V1a and V1b receptors on liver and pancreas functions and on the hypothalamic-pituitary-adrenal axis.
Introduction
The increasing prevalence of obesity and diabetes represents a major threat to public health by substantially increasing the risk of cardiovascular and renal disease morbidity and mortality. It is known for several decades that plasma AVP is elevated in type 1 and type 2 diabetes mellitus in humans [1, 2] and in experimental models of diabetes [3, 4] . However, the vasopressin-hydration axis emerged only recently, as a risk factor for impaired glucose homeostasis and diabetes.
Although AVP is well recognized as an antidiuretic hormone, accumulating evidence supports a role of AVP in regulation of blood glucose concentration. In the first section of this review, we report old and new data on the acute effects of AVP on glycaemia and potential organ targets of the hormone. In the subsequent section, we provide new insights into long-term effects of AVP on glucose homeostasis that have been revealed by recent in vivo experimental studies in mice and rats using genetic and pharmacological tools. Finally, the translation from animal findings to human was evidenced by epidemiological and genetic studies described in the last part of this review.
Overview of short-term effects of AVP on glucose metabolism with reference to potential role of V1a and V1b receptors It is well established that acute injection or sustained infusion of high dose of AVP induced a transient rise in blood glucose concentration in animals and humans [5] [6] [7] [8] . This hyperglycaemic effect may result from action of AVP on multiple targets. Indeed, AVP receptors are expressed in several organs involved in glucose metabolism. V1aR are highly expressed in liver, V1bR are principally found in pancreas and pituitary, and V1aR and V1bR are found in adrenals.
Ex vivo and in vitro studies have shown that binding of AVP to hepatic V1aR rapidly initiates glycogenolysis by increasing activity of glycogen phosphorylase [9] [10] [11] . It is noteworthy that species-related differences exist between human and rat with respect to hepatic V1aR abundance and AVP-stimulated glycogen phosphorylase activation [12] . Moreover, in vivo, glycogenolysis may be stimulated indirectly by vasoconstrictive effect of AVP through V1aR and resulting hypoxia within the liver [13, 14] . AVP also stimulates neoglucogenesis from neoglucogenic substrates as demonstrated in perfused liver or hepatocytes suspensions of starved rats [9, 15] .
On the other hand, it was shown that AVP increases both glucagon secretion and insulin concentration by activation of V1bR in alpha-and beta-cells of pancreatic islets [16, 17] . These effects occurred for different doses and/or in different proportions [16] . As illustrated in Fig. 1 , insulin was released in presence of high glucose concentration, whereas glucagon release was increased in presence of low concentration of glucose. Moreover, higher concentration of AVP was needed to increase insulin secretion than glucagon secretion. AVP, in physiological range of concentration (3-10 pmol L À1 ), evoked a dose-dependent secretion of glucagon from the rat pancreas perfused with buffer containing 5.5 mmol L À1 glucose [18] . In addition, crosstalk between glucagon receptor and V1aR and their signalling pathways has been described in hepatocytes [19, 20] . Besides its synthesis in hypothalamus and secretion from the posterior pituitary gland, AVP was also found to be secreted by the pancreas and immunolocalized in the perivascular compartment of the pancreas [18, 21] . These findings suggest a possible paracrine role of AVP in glucagon secretion. Further studies are needed to determine the role of AVP issued, respectively, from central and peripheral tissues in the control of glucagon secretion.
Although ex vivo and in vitro experiments showed a potential role V1aR and V1bR in the hyperglycaemic response to AVP, the extent of the contribution of these receptors in the whole effect of AVP remains unclear. In a recent in vivo experiment, in 6 h-fasted anesthetized rats, we showed that the V1aR antagonist SR49059 prevented the rise in glycaemia induced by acute iv injection AVP in a dose-dependent manner and injection of V1aR agonist FE201874 increased glycaemia. V1bR SSR149415 antagonist did not change the hyperglycaemic response to acute injection AVP, and V1bR agonist d(Leu4, Lys8)VP had no effect on glycaemia. Thus, these results support a major role of V1aR in the humoral control of glycaemia [22] .
However, whilst V1bR antagonist pretreatment did not change the basal insulinaemia or the insulin response to hyperglycaemia induced by AVP, it enhanced the fall in glucagon secretion after AVP injection [22] . This suggests that endogenous AVP constantly stimulates the glucagon secretion and thus participates in the physiological regulation of glucagon secretion in normal rats. This effect is probably small and detectable only in the absence of the main stimuli for glucagon secretion.
Besides, the potential involvement of AVP in the glucose homeostasis through action on peripheral organs, AVP participates also in the control of the hypothalamo-pituitary-adrenal (HPA) axis. It exerts a direct effect on ACTH secretion from the anterior pituitary and potentiates the stimulatory effect of corticotropin-releasing factor (CRF) from the hypothalamus through activation of V1bR [23, 24] . Moreover, AVP directly stimulates cortisol release in humans and corticosterone in rodents, by activating the V1aR in the adrenal cortex cells and stimulates epinephrine secretion by activating the V1bR in the chromaffin cells of the adrenal medulla (see review [25] ) which may subsequently contribute to hyperglycaemia.
Important for the function of HPA axis is the negative glucocorticoid feedback on CRF and ACTH secretions. Glucocorticoids could be also feedback inhibitors of AVP secretion [26, 27] . The possibility that dysfunction of the vasopressinergic system within the HPA axis may contribute to glucose disorders remains to be determined. Studies on patients with macronodular adrenal hyperplasia suggest that some forms of Cushing's syndrome could be accounted for by overresponsiveness to AVP leading to hypercortisolism [28] [29] [30] .
Long-term effects of AVP on glucose homeostasis in physiological and pathological experimental models As recalled in the first part of this review, most of the studies on AVP and glucose metabolism dealt with the short-term effects of the hormone on glycaemia or on target organs and cells. Here, we summarize recent advances in knowledge on longterm effect of AVP and the respective role of each AVP receptor on glucose homeostasis that have resulted from studies using rodents models with inactivation of genes encoding AVP or its receptors, and pharmacological tools.
Lessons from AVP receptor-and AVP-deficient models in metabolic disease
To investigate the role of V1aR and V1bR in glucose tolerance, we (KN) generated V1aR, V1bR and double-V1abR knockout mice. Brattleboro rats which cannot secrete AVP because of a deletion in the corresponding gene were used to delineate the global action of AVP on glucose homeostasis. Main results are summarized in Table 1 .
The plasma glucose level in V1aR-KO mice was significantly higher than that in wild-type (WT) mice in the fed condition. In addition, plasma glucose levels during a glucose tolerance test (GTT) were significantly higher in V1aR-KO mice than AVP, vasopressin; KO, knockout; N.C, no change; -, not examined.
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those in WT mice. However, plasma insulin levels were not altered between WT and V1aR-KO mice.
The glucose infusion rate in a hyperinsulinaemiceuglycemic clamp study was decreased in V1aR-KO mice compared with that in WT mice. These results indicate impaired glucose tolerance in V1aR-KO mice [31] . Akt phosphorylation in response to insulin stimulation in the adipocytes was significantly reduced in V1aR-KO mice compared with WT mice, suggesting that the altered insulin-signalling pathway produced by a deficient AVP/V1aR signal may result in reduced glucose uptake in fat, leading to insulin resistance and altered glucose tolerance [32] . The rate of hepatic glucose production in a hyperinsulinaemic-euglycemic clamp study was increased, and the glycogen content in livers from V1aR-KO mice was decreased [31] . The increased hepatic glucose production could also partially contribute to development of glucose intolerance in V1aR-KO mice. In addition, AVP directly regulates aldosterone secretion through the V1aR, which was expressed in the adrenal cortex. The plasma aldosterone level was decreased in V1aR-KO mice, which supports AVP resistance in V1aR-KO mice [31] . Thus, dysfunction of the AVP/V1aR-aldosterone system in V1aR-KO mice could cause a lower response to water recruitment by aldosterone, leading to decreased plasma volume. This decreased plasma volume could result in increased levels of blood glucose as well as increased levels of blood solutes, such as haematocrit and blood urea nitrogen [31] . V1aR-KO mice simultaneously showed AVP resistance, impaired glucose tolerance and increased hepatic glucose production. This suggests that AVP could be involved in maintaining blood glucose homeostasis by regulating body fluids, hepatic glucose production and insulin signalling, such as Akt.
On the other hand, the fasting plasma levels of insulin, glucagon and blood glucose were decreased in V1bR-KO mice compared with WT mice [33] . These findings indicate that blockade of AVP/V1bR signalling may affect glucose homeostasis in vivo. In addition, during the GTT, plasma glucose and insulin levels were lower in V1bR-KO mice compared with WT mice. The insulin tolerance test (ITT) revealed that the decrease in plasma glucose levels in V1bR-KO mice after insulin administration tended to be greater than in WT mice, suggesting that the plasma glucose-lowering effect of insulin was increased in V1bR-KO mice. Akt phosphorylation in response to insulin stimulation in the adipocytes was significantly enhanced in V1bR-KO mice compared with WT mice [33] . AVP stimulates insulin release in WT mice, but the AVP effect on insulin release was entirely lost in islets from V1bR-KO mice [34] . Although these results led to the prediction of higher plasma glucose levels in V1bR-KO mice, V1bR-KO mice unexpectedly exhibited lower plasma glucose levels, even after glucose loading. Therefore, hypersensitivity of adipose tissue to insulin in the V1bR-KO mice may have contributed to lower levels of plasma glucose. In addition to adipose tissue hypersensitivity to insulin in the V1bR-KO mice as described above, there may be other explanations for the lower plasma glucose in V1bR-KO mice. One explanation is that reduced glucagon secretion may have contributed to lower plasma glucose levels. AVP induces glucagon release as well as oxytocin on acells in the islets. A study with V1bR-KO mice showed that AVP stimulates glucagon release via the V1bR and oxytocin receptor in vitro [35] . Therefore, the V1bR deficiency could have led to reduced glucagon secretion, resulting in reduced plasma glucose levels. Another explanation is that glucocorticoids could have affected glucose homeostasis in V1bR-KO mice. Plasma adrenocorticotropic hormone and corticosterone levels were lower in V1bR-KO mice than in WT mice [36] . In rodents, corticosterone is known to be a key hormone that stimulates gluconeogenesis in the liver and increases plasma glucose levels [37, 38] . Thus, decreased corticosterone levels could have partially caused lower plasma glucose levels in the V1bR-KO mice [33] . The reduced plasma glucose levels observed in V1bR-KO mice may be a result of enhanced insulin sensitivity, reduced glucagon and/or reduced corticosterone levels.
As described above, AVP plays different roles in regulating glucose homeostasis via the V1aR and V1bR; AVP may enhance insulin sensitivity via the V1aR and suppress sensitivity via the V1bR. However, what about glucose tolerance in V1aR and V1bR double-KO (V1ab-receptor-KO) mice? The GTT revealed that glucose and insulin levels were higher in V1ab-receptor-KO mice, which is similar to the phenotype of V1aR-KO mice, but not to V1bR-KO mice, indicating that deficiency of both receptors resulted in the impaired glucose tolerance. Akt phosphorylation in response to insulin stimulation in the adipocytes was significantly reduced in V1ab-receptor-KO mice compared with in WT mice, which is similar to the finding in V1aR-KO mice. This result suggests that insulin sensitivity is decreased in V1ab-receptor-KO mice because of the suppressed insulin signal, which is similar to V1aR-KO mice [39] . These findings indicate that the effects of V1bR deficiency may not influence the development of glucose intolerance promoted by V1aR deficiency and that blockade of both receptors may lead to impaired glucose tolerance.
Based on these findings in the-KO mouse models as described above, Brattleboro rats, which genetically lack AVP, would be expected to display a glucose-intolerant phenotype, similar to that of V1ab-receptor-KO mice. However, Brattleboro rats showed enhanced glucose tolerance. The fasting plasma glucose level of Brattleboro rats is not altered. In contrast, the plasma insulin level of these rats was significantly lower than that of normal rats. This result suggests that insulin sensitivity is enhanced in Brattleboro rats [40] . In addition, the plasma glucose levels observed during GTT were consistently lower in Brattleboro rats than in normal rats. The plasma insulin levels were also lower in Brattleboro rats than in normal rats. These results indicate that Brattleboro rats have enhanced glucose tolerance [40] . These findings suggest that the AVP signals through the V2R as well as V1aR and V1bR may also be involved in regulating glucose homeostasis in vivo. The AVP/ V2R signal may affect glucose homeostasis by altering the regulation of water homeostasis. V2R were also found to be expressed in the heart, liver, muscle, white adipose tissue and brown adipose tissue [33] , all of which are insulin-sensitive tissues. This suggests the possibility that the AVP/ V2R signal influences insulin sensitivity in these insulin-sensitive tissues.
In summary, AVP regulates hepatic glucose production, insulin signalling and aldosterone secretion through the V1aR and regulates the insulin signal in fat, glucagon secretion from the pancreas and the corticosterone levels though the V1bR, which consequently affects glucose tolerance. In addition, the V2R may contribute to glucose tolerance regulated by AVP. Therefore, AVP may regulate glucose homeostasis via many pathways (Fig. 2) . The details of AVP actions on glucose homeostasis through the V1aR, V1bR and V2R
have not yet been fully clarified. We should clarify the mechanisms underlying the regulation of glucose homeostasis by AVP receptors using novel approaches such as tissue or cell type-specific conditional knockout models of AVP receptors in future studies.
Long-term impact of various levels of AVP on glucose homeostasis in the normal and in obese rats
To examine the long-term effect of AVP on glucose homeostasis, we (GV, NB) studied rats with various level of circulating AVP [22, 41] . AVP was altered chronically in both directions, by either sustained AVP infusion or an increase in water intake, daily food intake remaining equal between groups. Rats have no sign of volume dilution or contraction as there was no significant difference in plasma osmolality, natremia or haematocrit between groups. The infusion of AVP did not influence blood pressure. Fig. 2 Vasopressin may regulate glucose homeostasis via many pathways. AVP regulates hepatic glucose production, insulin signalling and aldosterone secretion through the V1aR and regulates the insulin signal in fat, glucagon secretion from the pancreas and the corticosterone levels through the V1bR, which consequently affects glucose tolerance. In addition, the V2R may contribute to glucose tolerance that is regulated by vasopressin.
This bidirectional protocol mimicked the wide interindividual variability of the usual AVP/copeptin concentration and osmotic thresholds for thirst and AVP secretion observed in humans [42] [43] [44] [45] .
We showed that chronic high-AVP level induced a time-dependent increase in fasting glycaemia, in two strains of healthy rats, the Sprague Dawley and the lean Zucker rats [22] .
In obese Zucker rats, a genetic model of insulin resistance, high-AVP level induced a marked increase in fasting insulinaemia compared to the control group, with no difference in blood glucose (Fig. 3) . Consistent with this observation, a glucose tolerance test induced higher glycaemia and insulinaemia responses in the high-AVP rats compared to control rats. The insulin tolerance test revealed also a lower sensitivity to insulin in high-AVP animals.
As detailed in the first section of this review, AVP may contribute to glucose metabolism through different pathways. In our study, we focussed on the role of V1aR and examined the effect of chronic V1aR blockade. In healthy rats, the increase in glycaemia induced by chronic AVP infusion was prevented by concomitant treatment with V1aR antagonist (Fig. 4a) .
In obese Zucker rats, after 4 weeks of V1aR-antagonist treatment, fasting insulinaemia was significantly lower in treated rats than in untreated control group. During the glucose tolerance test, the amplitude of glycaemic response was significantly decreased in V1aR antagonist-treated rats compared to control group, whereas amplitude of insulin response was not significantly different between groups (Fig. 4b ). V1aR blockade also corrected the low insulin sensitivity observed in obese rats. Of note, whereas low-AVP level induced by high water intake did not improve glucose tolerance in obese Zucker rats, it protects liver tissue from steatosis (Fig. 5) . Rats with high hydration had almost no steatosis after 2 weeks, in contrast to rats with normal hydration. The histological changes are associated with lower hepatic content in triacylglycerol and cholesterol and lower gene expression of proteins involved in lipogenesis [41] . V1aR antagonist treatment did not influence hepatic steatosis in obese Zucker rats (Taveau C, unpublished data). Thus, in this model, the effect of AVP on hepatic lipid accumulation and glucose tolerance is dissociated. The mechanisms responsible for the high hydration level effect on liver steatosis remain to be elucidated.
In summary, the results showed that sustained high AVP participates in the setting of basal glycaemia in healthy nonobese rats and aggravates glucose intolerance in obese rats through V1aR activation. They clearly support a causality link in the associations observed in epidemiological studies between high copeptin level or low water intake and the prevalence and incidence of hyperglycaemia, metabolic syndrome and type 2 diabetes (see details below).
High vasopressin level is a risk factor for glucose metabolism disorders in humans
An increasing body of data from clinical, epidemiological and genetic studies suggests that high vasopressin levels might be a risk factor for hyperglycaemia, diabetes and the metabolic syndrome. These results argue for the relevance in human pathology of the experimental data obtained in animal models, discussed in the previous sections of this manuscript, showing that the vasopressinhydration axis plays a role in glucose homeostasis.
Evidence supporting the beneficial effect of hydration in the prevention of hyperglycaemia in the general population
Roussel and co-workers assessed in 3615 participants from the DESIR study, a prospective cohort of the French general population, the association between self-declared water intake at baseline and the risk for impaired fasting glucose (IFG) or type 2 diabetes (T2DM) during a 9-year follow-up [46] . The daily intake of water, wine, beer or cider, and sweet beverages was categorized in a baseline
Glycaemia (mmol L questionnaire into six levels (none, <0.5 L, 0.5 to 1 L, 1 to 1.5 L, 1.5 to 2.0 L and >2 L). For the analyses, the levels were grouped into three classes for each of the beverages: <0.5 L, 0.5 to 1 L and >1 L. The daily water intake was negatively associated with the risk of new-onset hyperglycaemia, even after adjustment for multiple metabolic risk factors at baseline, including sex, age, BMI, fasting plasma glucose, total cholesterol, triglycerides, physical activity, smoking status and an insulin resistance index (HOMA-IR). A 25-35% decrease in the incidence of IFG/T2DM was observed by the higher classes of water intake, and the associations remained significant after further adjustments for the intake of the other beverages.
Plasma copeptin and risk for metabolic disorders in the general population
Vasopressin is not easily measurable because of its low concentration in the blood (10 À12 mol L À1 ), its small size and poor stability in blood samples. Copeptin, the stable C-terminal portion of the pre/ pro-vasopressin peptide, is easier to assay [47] and is currently used as surrogate marker of vasopressin and of the hydration status in clinical and epidemiological studies [45] .
Saleem and co-workers reported associations of plasma copeptin with insulin resistance and with the metabolic syndrome in cross-sectional analyses of two community-based cohorts: 1293 African American participants from Jackson, Mississippi, and 1197 non-Hispanic white participants from the Olmsted County, Minnesota [48] . Participants were selected on the basis of having an hypertensive sibship. In both cohorts, copeptin levels increased significantly with the presence of increasing number of metabolic syndrome components, including a high waist circumference, high blood pressure, hyperglycaemia, increased triglycerides and low HDL cholesterol. The higher quartile of baseline plasma copeptin, as compared to the lower quartile, was associated with 70-100% increase in the odds of having metabolic syndrome, and the association remained significant after adjustment for age, sex, smoking, statin use, serum creatinine, education, physical activity and diuretic use. In both cohorts, plasma copeptin was significantly associated with the HOMA-IR index of insulin resistance.
In a series of studies, Enh€ orning and co-workers analysed data from~5100 participants from the Swedish prospective population-based Malmo Diet and Cancer study-Cardiovascular Cohort (MDC-CC) [49] [50] [51] . At baseline, blood glucose and plasma insulin levels increased across increasing quartiles of copeptin suggesting an inverse correlation of copeptin with insulin sensitivity [50] , and plasma copeptin was associated with the prevalence of type 2 diabetes [49] . It was also associated with arterial hypertension, obesity, abdominal obesity and with the metabolic syndrome [49] . These associations remained significant after adjustment for age, sex, insulin and diabetes. High copeptin levels were also significantly associated with high fat intake, low physical activity and borderline significantly associated with low socio-economic status. The association between copeptin and components of the metabolic syndrome was not affected after adjustment for these environmental factors. At re-examination after an average follow-up of 15.8 years, the odds of incident diabetes increased across increasing quartiles of baseline copeptin and were 2-3 times greater for participants in the higher quartile than for those in the lower quartiles [50, 51] . Baseline plasma copeptin was also positively and independently associated with the incidence of abdominal obesity and microalbuminuria during follow-up [51] .
Circulating levels of vasopressin and copeptin are systematically higher in men than in women [45, 49, [52] [53] [54] [55] . We (NB, GV) observed median plasma levels of both peptides~60% higher in men than in women in a French population-based cohort [45, 56] . We have also observed higher copeptin levels in men in cohorts of patients with type 1 [53] or with type 2 diabetes [52] . The physiological basis of this sex-related difference and its impact on vasopressin physiological and pathophysiological effects are unclear. Interestingly, Abassi and co-workers reported a stronger association in women than in men between baseline plasma copeptin and the incidence of type 2 diabetes during an 8-year follow-up of 7972 participants of the Dutch population-based PRE-VEND study [54] . The risk for the incidence of diabetes associated with the higher quartile of plasma copeptin or with 1 unit of log(copeptin) was two times higher in women than in men, and the association was independent of confounding factors such as, age, family history of diabetes, waist circumference, hypertension, HDL cholesterol, triglycerides and 24-h urinary albumin excretion. In contrast, Then and co-workers reported associations of plasma copeptin with the prevalence of type 2 diabetes only in men, in cross-sectional analyses 752 men and 788 women from the German population-based-KORA F4 study [55] . Wannamethee and co-workers analysed data from 4097 older men (aged 60-79 years) from the prospective British Regional Heart Study, drawn from general practice in 24 British towns [57] . Baseline copeptin was associated with renal dysfunction (lower eGFR), insulin resistance (HOMA-IR), metabolic risk factors (waist circumference, blood pressure, triglycerides, etc.), C-reactive protein but, interestingly, not with plasma glucose nor with HbA1c. The risk of incident diabetes during a 13-year follow-up was higher only for the top quintile of copeptin distribution, 50-80% higher as compared to the other quintiles. The association persisted after adjustment for other diabetes risk factors, including age, waist circumference, physical activity, social class, use of statins or antihypertensive drugs, blood pressure, blood lipids, glucose and HOMA-IR at baseline. Unfortunately, no data from women were available in that study.
Genetic epidemiology investigations of vasopressin and its receptors in metabolic disorders
We (GV, NB) have investigated associations of plasma copeptin at baseline and of allelic variations in the AVP gene with insulin secretion, insulin sensitivity and the risk for impaired fasting glucose (IFG) and type 2 diabetes mellitus (T2DM) in the DESIR study, a prospective cohort of the French general population [58] . We confirmed in that study that high plasma copeptin at baseline is associated with decreased insulin sensitivity and with increased risk for IFG or T2DM during a 9-year follow-up (Fig. 6) . These results complemented our previous observation in that cohort that water intake was inversely and independently associated with the risk of developing hyperglycaemia [46] and that circulating levels of copeptin reflected the hydration status (water intake and urine osmolarity) [45] . We have also observed associations between a set of tagSNPs in the AVP gene and decreased insulin sensitivity (HOMA index) at baseline and the incidence of hyperglycaemia and diabetes during the follow-up [58] . The genotypes associated with these metabolic phenotypes were also associated with increased plasma copeptin in men, but not in women. The allelic associations observed in our study suggest a pattern of mendelian randomization [59] , at least in men, and support the causality of the association between vasopressin and hyperglycaemia. However, the genetic basis of the association of the tagSNPs with the phenotypes is unclear. None had obvious functional properties that could predict deleterious effects on AVP expression or function. Possible nonexclusive explanations for the sexual dimorphism of the results included the uncertainty regarding the functional variant and lower statistical power related to the lower plasma copeptin concentration and the smaller range of the distribution of plasma copeptin in women than in men.
Genetic epidemiology studies on the vasopressin system and metabolic phenotypes are scarce.
Enh€ orning and co-workers investigated associations of 4 tagSNPs in the vasopressin receptor 1A gene (AVPR1A) with metabolic phenotypes iñ 5200 participants from the Swedish populationbased MDC-CC study [60] . They observed associations of the T allele of rs1042615 with an increased prevalence of type 2 diabetes in the subset of men with a high fat intake or who were overweight, whilst no association was observed in women. The same investigators reported recently an association of rs35810727, a tagSNP in the vasopressin receptor 1B gene (AVPR1B), with the BMI in~6100 MDC-CC participants and in 24,300 participants of the MDC replication cohort [61] . The major A-allele, associated with higher BMI in both cohorts, was also associated with the prevalence of type 2 diabetes in the replication cohort, but not in MDC-CC.
Conclusion
A role of AVP in glucose metabolism was suspected since long time. Recent data on rodents and humans demonstrated that high circulating vasopressin concentration is a risk factor for development of hyperglycaemia, metabolic syndrome and type 2 diabetes.
In vivo findings on whole animals and genetic epidemiological studies suggested that activation of V1aR plays a predominant role in regulating glucose homeostasis. However, studies on mice or rat deficient in one component of the AVP system showed that each receptor type, V1a, V1b and V2, may participate to the regulation of the glucose metabolism. The complex interactions between receptor signalling and possible compensatory phenomenon in absence of one receptor subtype remained to be clarified.
Overall, these findings provide a rationale for intervention studies aiming to evaluate whether a reduction in AVP secretion or action could improve the metabolic status in people who are at risk of diabetes and have a high copeptin concentration/ low hydration status. This may be achieved by moderate increase in water intake as it is actually tested for slowing progression of chronic kidney disease [62, 63] . Attention should be paid to the use of vaptan (V2 antagonist) because they induced secondarily an increase in water intake but also enhanced AVP secretion and thus V1aR-mediated action.
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